A Phase 3 interventional study of 5-Fluorouracil and Capecitabine in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 172 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Stomach Neoplasms by Hoffmann-La Roche — none open to participants now, 2 under way, none of them phase 3. Stomach Neoplasms · Hoffmann-La Roche.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2013, is one of 7 in phase 3, and was the 16th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →None of the 29 studies in Stomach Neoplasms by Hoffmann-La Roche is open now. The open studies under Stomach Neoplasms, anywhere →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 8 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 780 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 158 across the 23 interventional studies, 503 across the 6 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram [mg/kg] intravenously [IV] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Drug: 5-Fluorouracil · Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab
Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Drug: 5-Fluorouracil · Drug: Capecitabine · Drug: Cisplatin · Drug: Placebo · Drug: Trastuzumab
Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
Also known as: Xeloda
Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Also known as: Perjeta, RO4368451
Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Also known as: Herceptin, RO0452317
Overall Survival
Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.
Time frame: From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)
Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria
Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.
Time frame: Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)
Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria
The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)
Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria
The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months)
Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria
Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.
Time frame: Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)
Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria
The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.
Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)
Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)
Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)
The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.
Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Time frame: Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)
Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score
The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
Time frame: Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)
Maximum Serum Concentration (Cmax) of Pertuzumab
Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)
Cmax of Trastuzumab
Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)
Minimum Serum Concentration (Cmin) of Pertuzumab
Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)
Cmin of Trastuzumab
Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)
| Milestone | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Started | 388 | 392 |
| Did not receive any study treatment | 4 | 3 |
| Received at least one dose of pertuzumab | 384 | 1 |
| Received placebo (no pertuzumab) | 0 | 388 |
| Completed | 60 | 46 |
| Not completed | 328 | 346 |
| Withdrew: Death | 300 | 319 |
| Withdrew: Lost to follow-up | 6 | 7 |
| Withdrew: Withdrawal by subject | 18 | 14 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Non-compliance | 0 | 1 |
| Withdrew: Reason not specified | 2 | 5 |
Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.
| Months | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Primary Analysis | 17.5 (16.2 to 19.3) | 14.2 (12.9 to 15.5) |
| Final Analysis | 18.1 (16.2 to 19.5) | 14.2 (12.9 to 15.7) |
Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.
| months | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Primary Analysis | 8.5 (8.2 to 9.7) | 7.0 (6.4 to 8.2) |
| Final Analysis | 8.5 (8.3 to 9.7) | 7.2 (6.4 to 8.2) |
The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
| Percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Objective Response (CR + PR) | 56.7 (51.33 to 61.95) | 48.3 (42.97 to 53.65) |
| Complete Response (CR) | 5.1 (3.07 to 7.98) | 0.9 (0.18 to 2.47) |
| Partial Response (PR) | 51.6 (46.20 to 56.91) | 47.4 (42.13 to 52.80) |
| Stable Disease (SD) | 27.9 (23.29 to 32.93) | 33.0 (28.06 to 38.14) |
| Progressive Disease (PD) | 4.8 (2.85 to 7.64) | 8.0 (5.35 to 11.29) |
| Not Evaluable/Missing | 10.5 (7.53 to 14.24) | 10.8 (7.75 to 14.52) |
The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.
| Percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Objective Response (CR + PR) | 57.0 (51.62 to 62.22) | 48.6 (43.25 to 53.94) |
| Complete Response (CR) | 5.7 (3.51 to 8.66) | 2.0 (0.80 to 4.05) |
| Partial Response (PR) | 51.3 (45.92 to 56.62) | 46.6 (41.29 to 51.95) |
| Stable Disease (SD) | 27.6 (23.02 to 32.63) | 32.7 (27.79 to 37.84) |
| Progressive Disease (PD) | 4.8 (2.85 to 7.64) | 8.2 (5.59 to 11.62) |
| Not Evaluable/Missing | 10.5 (7.53 to 14.24) | 10.5 (7.51 to 14.20) |
Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.
| months | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Primary Analysis | 10.2 (8.4 to 10.7) | 8.4 (6.8 to 8.7) |
| Final Analysis | 10.2 (8.5 to 11.6) | 8.4 (6.7 to 9.0) |
The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria | 84.6 (80.41 to 88.23) | 81.3 (76.77 to 85.19) |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.
| Participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Any Adverse Event (AE) | 381 | 385 |
| AE with Fatal Outcome | 27 | 31 |
| Serious AE | 178 | 156 |
| Grade 3-5 AE | 310 | 288 |
| AE Leading to Pertuz/Pbo & Trastuz Discontinuation | 48 | 46 |
| AE Leading to Dose Interruption &/or Dose Delay | 110 | 94 |
The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.
| Participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Symptomatic LVSD | 3 | 1 |
| Asymptomatic LVSD | 20 | 18 |
The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
| score on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Appetite Loss: Cycle 1 (Baseline) | 26.68 ± 28.65 | 27.59 ± 29.96 |
| Appetite Loss: Change at Cycle 2 | 6.57 ± 33.18 | 0.97 ± 35.86 |
| Appetite Loss: Change at Cycle 3 | 3.63 ± 36.19 | 3.81 ± 36.76 |
| Appetite Loss: Change at Cycle 4 | 5.24 ± 34.20 | 0.79 ± 34.33 |
| Appetite Loss: Change at Cycle 5 | 4.55 ± 36.50 | 2.90 ± 35.85 |
| Appetite Loss: Change at Cycle 6 | 3.94 ± 36.07 | -0.39 ± 36.86 |
| Appetite Loss: Change at Cycle 7 | 2.07 ± 38.05 | 1.61 ± 35.98 |
| Appetite Loss: Change at Cycle 8 | -2.42 ± 33.81 | -3.69 ± 34.20 |
| Appetite Loss: Change at Cycle 9 | -6.67 ± 31.92 | -4.76 ± 31.67 |
| Appetite Loss: Change at Cycle 10 | -8.06 ± 32.52 | -6.63 ± 28.48 |
| Appetite Loss: Change at Cycle 11 | -9.36 ± 33.19 | -9.68 ± 27.38 |
| Appetite Loss: Change at Cycle 12 | -9.22 ± 33.73 | -9.05 ± 28.51 |
| Appetite Loss: Change at Cycle 13 | -10.17 ± 31.10 | -10.81 ± 29.18 |
| Appetite Loss: Change at Cycle 14 | -12.10 ± 31.96 | -12.09 ± 30.32 |
| Appetite Loss: Change at Cycle 15 | -8.21 ± 32.96 | -9.18 ± 29.81 |
| Appetite Loss: Change at Cycle 16 | -6.03 ± 33.07 | -10.59 ± 28.74 |
| Appetite Loss: Change at Cycle 17 | -6.55 ± 29.29 | -9.91 ± 29.05 |
| Appetite Loss: Change at Cycle 18 | -4.90 ± 31.25 | -14.08 ± 27.98 |
| Appetite Loss: Change at Cycle 19 | -8.33 ± 31.34 | -13.13 ± 28.57 |
| Appetite Loss: Change at Cycle 20 | -3.97 ± 31.65 | -13.23 ± 29.66 |
| Appetite Loss: Change at Cycle 21 | -5.91 ± 31.01 | -14.20 ± 32.76 |
| Appetite Loss: Change at Cycle 22 | -4.98 ± 34.45 | -16.31 ± 29.38 |
| Appetite Loss: Change at Cycle 23 | -6.35 ± 36.84 | -11.36 ± 35.90 |
| Appetite Loss: Change at Cycle 24 | -7.78 ± 33.82 | -13.33 ± 30.00 |
| Appetite Loss: Change at Cycle 25 | -7.05 ± 35.14 | -12.04 ± 31.02 |
| Appetite Loss: Change at Cycle 26 | -7.48 ± 34.87 | -12.50 ± 32.52 |
| Appetite Loss: Change at Cycle 27 | -10.08 ± 33.76 | -9.20 ± 28.03 |
| Appetite Loss: Change at Cycle 28 | -10.00 ± 32.20 | -11.54 ± 29.73 |
| Appetite Loss: Change at PT Visit 1 | 7.30 ± 36.86 | 2.64 ± 33.14 |
| Appetite Loss: Change at PT Visit 2 | -0.33 ± 33.83 | 4.55 ± 34.53 |
| Cognitive Functional Scale: Cycle 1 (Baseline) | 87.95 ± 17.32 | 88.22 ± 16.18 |
| Cognitive Functional Scale: Change at Cycle 2 | -1.90 ± 17.82 | -1.81 ± 16.93 |
| Cognitive Functional Scale: Change at Cycle 3 | -0.83 ± 17.11 | -3.17 ± 18.30 |
| Cognitive Functional Scale: Change at Cycle 4 | -2.04 ± 17.78 | -2.99 ± 19.28 |
| Cognitive Functional Scale: Change at Cycle 5 | -3.04 ± 19.09 | -4.59 ± 19.59 |
| Cognitive Functional Scale: Change at Cycle 6 | -5.10 ± 19.23 | -3.84 ± 19.00 |
| Cognitive Functional Scale: Change at Cycle 7 | -4.34 ± 19.52 | -4.31 ± 19.09 |
| Cognitive Functional Scale: Change at Cycle 8 | -3.15 ± 17.90 | -3.30 ± 17.59 |
| Cognitive Functional Scale: Change at Cycle 9 | -2.22 ± 18.53 | -4.59 ± 18.53 |
| Cognitive Functional Scale: Change at Cycle 10 | -3.32 ± 19.44 | -3.11 ± 18.50 |
| Cognitive Functional Scale: Change at Cycle 11 | -2.83 ± 18.44 | -3.44 ± 17.06 |
| Cognitive Functional Scale: Change at Cycle 12 | -3.35 ± 20.00 | -2.52 ± 18.16 |
| Cognitive Functional Scale: Change at Cycle 13 | -1.79 ± 19.04 | -3.60 ± 17.89 |
| Cognitive Functional Scale: Change at Cycle 14 | -1.98 ± 19.00 | -2.29 ± 17.56 |
| Cognitive Functional Scale: Change at Cycle 15 | -1.15 ± 18.47 | -2.38 ± 16.05 |
| Cognitive Functional Scale: Change at Cycle 16 | -2.73 ± 17.16 | -2.55 ± 17.16 |
| Cognitive Functional Scale: Change at Cycle 17 | -2.53 ± 17.21 | -1.13 ± 15.44 |
| Cognitive Functional Scale: Change at Cycle 18 | -2.78 ± 18.18 | 0.47 ± 16.42 |
| Cognitive Functional Scale: Change at Cycle 19 | -1.04 ± 18.07 | 0.00 ± 14.62 |
| Cognitive Functional Scale: Change at Cycle 20 | -2.18 ± 19.67 | 0.79 ± 15.68 |
| Cognitive Functional Scale: Change at Cycle 21 | -2.11 ± 20.56 | 0.62 ± 16.50 |
| Cognitive Functional Scale: Change at Cycle 22 | -4.73 ± 18.98 | -0.71 ± 18.04 |
| Cognitive Functional Scale: Change at Cycle 23 | -2.38 ± 19.60 | 1.14 ± 17.75 |
| Cognitive Functional Scale: Change at Cycle 24 | -2.78 ± 19.69 | 1.25 ± 16.18 |
| Cognitive Functional Scale: Change at Cycle 25 | -5.45 ± 16.41 | -0.93 ± 18.66 |
| Cognitive Functional Scale: Change at Cycle 26 | -2.38 ± 16.32 | -1.56 ± 18.63 |
| Cognitive Functional Scale: Change at Cycle 27 | -3.88 ± 18.84 | -1.15 ± 18.33 |
| Cognitive Functional Scale: Change at Cycle 28 | -3.75 ± 15.78 | 0.00 ± 20.00 |
| Cognitive Functional Scale: Change at PT Visit 1 | -9.13 ± 21.90 | -9.16 ± 20.02 |
| Cognitive Functional Scale: Change at PT Visit 2 | -8.42 ± 20.22 | -11.21 ± 22.48 |
| Constipation Symptom Scale: Cycle 1 (Baseline) | 20.43 ± 28.45 | 18.41 ± 27.13 |
| Constipation Symptom Scale: Change at Cycle 2 | -5.39 ± 27.05 | 0.29 ± 27.23 |
| Constipation Symptom Scale: Change at Cycle 3 | -7.48 ± 28.98 | -2.11 ± 27.65 |
| Constipation Symptom Scale: Change at Cycle 4 | -5.32 ± 29.21 | -3.73 ± 28.26 |
| Constipation Symptom Scale: Change at Cycle 5 | -5.94 ± 29.15 | -1.28 ± 27.64 |
| Constipation Symptom Scale: Change at Cycle 6 | -7.13 ± 29.65 | -2.33 ± 30.24 |
| Constipation Symptom Scale: Change at Cycle 7 | -8.13 ± 30.11 | -4.09 ± 29.06 |
| Constipation Symptom Scale: Change at Cycle 8 | -8.05 ± 30.90 | -4.45 ± 27.32 |
| Constipation Symptom Scale: Change at Cycle 9 | -10.00 ± 27.10 | -5.61 ± 26.74 |
| Constipation Symptom Scale: Change at Cycle 10 | -9.32 ± 29.56 | -7.43 ± 26.81 |
| Constipation Symptom Scale: Change at Cycle 11 | -9.16 ± 29.60 | -6.88 ± 27.84 |
| Constipation Symptom Scale: Change at Cycle 12 | -10.27 ± 29.04 | -7.25 ± 25.39 |
| Constipation Symptom Scale: Change at Cycle 13 | -11.19 ± 29.55 | -5.76 ± 26.27 |
| Constipation Symptom Scale: Change at Cycle 14 | -11.60 ± 27.11 | -6.21 ± 26.00 |
| Constipation Symptom Scale: Change at Cycle 15 | -10.51 ± 26.59 | -7.14 ± 24.52 |
| Constipation Symptom Scale: Change at Cycle 16 | -8.62 ± 24.91 | -7.45 ± 25.39 |
| Constipation Symptom Scale: Change at Cycle 17 | -8.33 ± 24.30 | -5.86 ± 18.59 |
| Constipation Symptom Scale: Change at Cycle 18 | -7.52 ± 22.93 | -6.57 ± 26.20 |
| Constipation Symptom Scale: Change at Cycle 19 | -3.47 ± 25.81 | -3.03 ± 25.97 |
| Constipation Symptom Scale: Change at Cycle 20 | -3.97 ± 26.08 | -4.76 ± 26.68 |
| Constipation Symptom Scale: Change at Cycle 21 | -3.80 ± 29.23 | -9.26 ± 25.42 |
| Constipation Symptom Scale: Change at Cycle 22 | -4.98 ± 28.58 | -8.51 ± 27.34 |
| Constipation Symptom Scale: Change at Cycle 23 | -6.35 ± 28.62 | -8.33 ± 26.04 |
| Constipation Symptom Scale: Change at Cycle 24 | -7.78 ± 27.01 | -10.00 ± 26.37 |
| Constipation Symptom Scale: Change at Cycle 25 | -7.05 ± 29.77 | -9.26 ± 28.30 |
| Constipation Symptom Scale: Change at Cycle 26 | -6.12 ± 30.94 | -6.25 ± 23.09 |
| Constipation Symptom Scale: Change at Cycle 27 | -7.75 ± 28.95 | -10.34 ± 26.88 |
| Constipation Symptom Scale: Change at Cycle 28 | -6.67 ± 26.37 | -6.41 ± 21.12 |
| Constipation Symptom Scale: Change at PT Visit 1 | -6.78 ± 31.45 | -4.62 ± 26.19 |
| Constipation Symptom Scale: Change at PT Visit 2 | -6.93 ± 28.41 | -0.91 ± 31.11 |
| Diarrhea Symptom Scale: Cycle 1 (Baseline) | 8.87 ± 17.70 | 9.16 ± 18.87 |
| Diarrhea Symptom Scale: Change at Cycle 2 | 15.12 ± 30.42 | 5.20 ± 23.79 |
| Diarrhea Symptom Scale: Change at Cycle 3 | 14.64 ± 27.71 | 4.99 ± 26.10 |
| Diarrhea Symptom Scale: Change at Cycle 4 | 14.13 ± 27.15 | 4.63 ± 24.07 |
| Diarrhea Symptom Scale: Change at Cycle 5 | 13.17 ± 25.47 | 4.99 ± 23.70 |
| Diarrhea Symptom Scale: Change at Cycle 6 | 14.81 ± 27.01 | 2.47 ± 23.76 |
| Diarrhea Symptom Scale: Change at Cycle 7 | 12.26 ± 23.74 | 2.92 ± 23.44 |
| Diarrhea Symptom Scale: Change at Cycle 8 | 8.91 ± 23.56 | 2.61 ± 23.53 |
| Diarrhea Symptom Scale: Change at Cycle 9 | 6.83 ± 23.76 | 2.04 ± 21.25 |
| Diarrhea Symptom Scale: Change at Cycle 10 | 6.63 ± 23.97 | 0.60 ± 20.91 |
| Diarrhea Symptom Scale: Change at Cycle 11 | 5.26 ± 21.80 | 2.60 ± 20.36 |
| Diarrhea Symptom Scale: Change at Cycle 12 | 3.98 ± 22.30 | 1.92 ± 19.97 |
| Diarrhea Symptom Scale: Change at Cycle 13 | 4.29 ± 24.27 | 1.50 ± 19.27 |
| Diarrhea Symptom Scale: Change at Cycle 14 | 3.95 ± 24.45 | 0.98 ± 20.15 |
| Diarrhea Symptom Scale: Change at Cycle 15 | 3.33 ± 23.79 | 1.02 ± 19.42 |
| Diarrhea Symptom Scale: Change at Cycle 16 | 5.46 ± 21.06 | 3.14 ± 15.10 |
| Diarrhea Symptom Scale: Change at Cycle 17 | 2.68 ± 21.05 | 2.25 ± 14.94 |
| Diarrhea Symptom Scale: Change at Cycle 18 | 3.59 ± 21.95 | 3.29 ± 17.95 |
| Diarrhea Symptom Scale: Change at Cycle 19 | 3.82 ± 19.86 | 2.02 ± 16.41 |
| Diarrhea Symptom Scale: Change at Cycle 20 | 5.95 ± 19.47 | 3.70 ± 17.05 |
| Diarrhea Symptom Scale: Change at Cycle 21 | 3.80 ± 23.26 | 1.85 ± 16.40 |
| Diarrhea Symptom Scale: Change at Cycle 22 | 6.97 ± 24.98 | 4.26 ± 17.88 |
| Diarrhea Symptom Scale: Change at Cycle 23 | 6.88 ± 21.72 | 8.33 ± 20.49 |
| Diarrhea Symptom Scale: Change at Cycle 24 | 7.22 ± 22.21 | 3.33 ± 16.54 |
| Diarrhea Symptom Scale: Change at Cycle 25 | 8.97 ± 23.91 | 2.78 ± 14.64 |
| Diarrhea Symptom Scale: Change at Cycle 26 | 5.44 ± 21.89 | 5.21 ± 20.93 |
| Diarrhea Symptom Scale: Change at Cycle 27 | 3.88 ± 22.07 | 3.45 ± 16.29 |
| Diarrhea Symptom Scale: Change at Cycle 28 | 7.50 ± 27.72 | 2.56 ± 16.12 |
| Diarrhea Symptom Scale: Change at PT Visit 1 | 8.14 ± 26.00 | 1.98 ± 24.35 |
| Diarrhea Symptom Scale: Change at PT Visit 2 | 7.26 ± 25.65 | 4.24 ± 29.65 |
| Dyspnoea Symptom Scale: Cycle 1 (Baseline) | 12.07 ± 17.99 | 12.65 ± 20.20 |
| Dyspnoea Symptom Scale: Change at Cycle 2 | -0.50 ± 19.04 | 0.29 ± 19.72 |
| Dyspnoea Symptom Scale: Change at Cycle 3 | -0.31 ± 20.18 | -0.32 ± 20.38 |
| Dyspnoea Symptom Scale: Change at Cycle 4 | 1.23 ± 20.31 | 1.81 ± 21.08 |
| Dyspnoea Symptom Scale: Change at Cycle 5 | 2.58 ± 20.62 | 1.39 ± 21.18 |
| Dyspnoea Symptom Scale: Change at Cycle 6 | 3.20 ± 23.79 | 0.39 ± 20.55 |
| Dyspnoea Symptom Scale: Change at Cycle 7 | 0.00 ± 21.94 | 0.59 ± 20.07 |
| Dyspnoea Symptom Scale: Change at Cycle 8 | -0.14 ± 21.99 | 0.93 ± 20.56 |
| Dyspnoea Symptom Scale: Change at Cycle 9 | -1.12 ± 20.51 | 0.17 ± 18.95 |
| Dyspnoea Symptom Scale: Change at Cycle 10 | -0.54 ± 21.56 | 1.00 ± 16.99 |
| Dyspnoea Symptom Scale: Change at Cycle 11 | -2.16 ± 19.58 | -1.29 ± 17.77 |
| Dyspnoea Symptom Scale: Change at Cycle 12 | -2.53 ± 19.75 | -0.71 ± 18.95 |
| Dyspnoea Symptom Scale: Change at Cycle 13 | -1.43 ± 20.34 | -1.20 ± 16.77 |
| Dyspnoea Symptom Scale: Change at Cycle 14 | -1.98 ± 19.00 | -2.61 ± 17.98 |
| Dyspnoea Symptom Scale: Change at Cycle 15 | -2.84 ± 21.26 | 2.72 ± 18.95 |
| Dyspnoea Symptom Scale: Change at Cycle 16 | -1.45 ± 20.42 | 1.18 ± 18.86 |
| Dyspnoea Symptom Scale: Change at Cycle 17 | -1.82 ± 20.61 | 0.90 ± 19.87 |
| Dyspnoea Symptom Scale: Change at Cycle 18 | -0.98 ± 20.15 | -2.35 ± 18.10 |
| Dyspnoea Symptom Scale: Change at Cycle 19 | -1.74 ± 20.73 | 0.51 ± 18.15 |
| Dyspnoea Symptom Scale: Change at Cycle 20 | -1.19 ± 20.98 | -1.06 ± 16.90 |
| Dyspnoea Symptom Scale: Change at Cycle 21 | 1.27 ± 22.29 | -0.62 ± 19.95 |
| Dyspnoea Symptom Scale: Change at Cycle 22 | -1.99 ± 22.38 | 0.71 ± 14.73 |
| Dyspnoea Symptom Scale: Change at Cycle 23 | -1.59 ± 21.94 | 1.52 ± 14.30 |
| Dyspnoea Symptom Scale: Change at Cycle 24 | 1.11 ± 22.10 | -1.67 ± 12.96 |
| Dyspnoea Symptom Scale: Change at Cycle 25 | 0.64 ± 21.38 | -3.70 ± 15.49 |
| Dyspnoea Symptom Scale: Change at Cycle 26 | 0.00 ± 22.57 | 1.04 ± 23.16 |
| Dyspnoea Symptom Scale: Change at Cycle 27 | 0.78 ± 21.19 | 3.45 ± 22.44 |
| Dyspnoea Symptom Scale: Change at Cycle 28 | 1.67 ± 21.28 | 3.85 ± 17.20 |
| Dyspnoea Symptom Scale: Change at PT Visit 1 | 6.97 ± 26.98 | 6.77 ± 23.82 |
| Dyspnoea Symptom Scale: Change at PT Visit 2 | 3.30 ± 23.81 | 9.39 ± 26.76 |
| Emotional Functional Scale: Cycle 1 (Baseline) | 76.90 ± 20.21 | 76.56 ± 19.84 |
| Emotional Functional Scale: Change at Cycle 2 | 3.53 ± 16.84 | 3.05 ± 18.49 |
| Emotional Functional Scale: Change at Cycle 3 | 2.65 ± 18.63 | 3.96 ± 19.95 |
| Emotional Functional Scale: Change at Cycle 4 | 3.10 ± 21.11 | 3.67 ± 20.44 |
| Emotional Functional Scale: Change at Cycle 5 | 2.62 ± 19.97 | 2.74 ± 21.72 |
| Emotional Functional Scale: Change at Cycle 6 | 1.01 ± 19.64 | 4.93 ± 21.00 |
| Emotional Functional Scale: Change at Cycle 7 | 1.72 ± 21.09 | 4.41 ± 20.18 |
| Emotional Functional Scale: Change at Cycle 8 | 3.43 ± 20.66 | 5.66 ± 19.63 |
| Emotional Functional Scale: Change at Cycle 9 | 4.72 ± 20.10 | 4.78 ± 19.45 |
| Emotional Functional Scale: Change at Cycle 10 | 3.72 ± 21.76 | 6.74 ± 18.13 |
| Emotional Functional Scale: Change at Cycle 11 | 5.85 ± 19.64 | 4.96 ± 19.21 |
| Emotional Functional Scale: Change at Cycle 12 | 4.93 ± 21.38 | 5.24 ± 19.14 |
| Emotional Functional Scale: Change at Cycle 13 | 5.00 ± 23.07 | 5.18 ± 17.95 |
| Emotional Functional Scale: Change at Cycle 14 | 5.93 ± 22.90 | 6.29 ± 19.03 |
| Emotional Functional Scale: Change at Cycle 15 | 6.03 ± 22.13 | 5.19 ± 19.61 |
| Emotional Functional Scale: Change at Cycle 16 | 5.17 ± 23.20 | 5.29 ± 20.81 |
| Emotional Functional Scale: Change at Cycle 17 | 6.01 ± 23.55 | 6.31 ± 18.70 |
| Emotional Functional Scale: Change at Cycle 18 | 3.68 ± 24.11 | 5.87 ± 19.39 |
| Emotional Functional Scale: Change at Cycle 19 | 4.69 ± 26.01 | 5.56 ± 18.68 |
| Emotional Functional Scale: Change at Cycle 20 | 3.47 ± 26.92 | 5.42 ± 17.91 |
| Emotional Functional Scale: Change at Cycle 21 | 4.54 ± 26.55 | 6.48 ± 22.00 |
| Emotional Functional Scale: Change at Cycle 22 | 5.35 ± 28.67 | 6.91 ± 18.66 |
| Emotional Functional Scale: Change at Cycle 23 | 5.82 ± 28.42 | 6.63 ± 21.00 |
| Emotional Functional Scale: Change at Cycle 24 | 5.28 ± 26.22 | 8.54 ± 19.57 |
| Emotional Functional Scale: Change at Cycle 25 | 5.93 ± 25.48 | 8.80 ± 20.89 |
| Emotional Functional Scale: Change at Cycle 26 | 5.44 ± 27.77 | 5.99 ± 16.15 |
| Emotional Functional Scale: Change at Cycle 27 | 7.56 ± 28.34 | 5.75 ± 18.51 |
| Emotional Functional Scale: Change at Cycle 28 | 7.08 ± 25.43 | 7.05 ± 18.96 |
| Emotional Functional Scale: Change at PT Visit 1 | -5.48 ± 23.16 | -3.92 ± 23.28 |
| Emotional Functional Scale: Change at PT Visit 2 | -2.64 ± 23.33 | -4.47 ± 23.34 |
| Fatigue Symptom Scale: Cycle 1 (Baseline) | 31.96 ± 23.46 | 32.27 ± 21.92 |
| Fatigue Symptom Scale: Change at Cycle 2 | 3.13 ± 19.80 | 2.32 ± 21.57 |
| Fatigue Symptom Scale: Change at Cycle 3 | 1.41 ± 22.65 | 3.19 ± 22.97 |
| Fatigue Symptom Scale: Change at Cycle 4 | 2.77 ± 23.14 | 1.58 ± 24.04 |
| Fatigue Symptom Scale: Change at Cycle 5 | 3.87 ± 25.75 | 3.05 ± 24.29 |
| Fatigue Symptom Scale: Change at Cycle 6 | 4.37 ± 25.64 | 2.62 ± 23.68 |
| Fatigue Symptom Scale: Change at Cycle 7 | 2.36 ± 26.79 | 0.97 ± 23.44 |
| Fatigue Symptom Scale: Change at Cycle 8 | -0.19 ± 25.00 | -1.18 ± 22.74 |
| Fatigue Symptom Scale: Change at Cycle 9 | -2.38 ± 22.69 | -2.01 ± 22.84 |
| Fatigue Symptom Scale: Change at Cycle 10 | -3.41 ± 24.69 | -3.08 ± 22.41 |
| Fatigue Symptom Scale: Change at Cycle 11 | -4.35 ± 22.66 | -3.44 ± 21.21 |
| Fatigue Symptom Scale: Change at Cycle 12 | -3.14 ± 24.56 | -4.60 ± 24.39 |
| Fatigue Symptom Scale: Change at Cycle 13 | -4.57 ± 23.31 | -4.50 ± 21.47 |
| Fatigue Symptom Scale: Change at Cycle 14 | -6.75 ± 24.32 | -6.54 ± 22.89 |
| Fatigue Symptom Scale: Change at Cycle 15 | -5.47 ± 24.68 | -4.99 ± 22.40 |
| Fatigue Symptom Scale: Change at Cycle 16 | -3.54 ± 24.81 | -6.93 ± 21.89 |
| Fatigue Symptom Scale: Change at Cycle 17 | -4.27 ± 25.50 | -3.45 ± 21.91 |
| Fatigue Symptom Scale: Change at Cycle 18 | -4.14 ± 24.42 | -8.92 ± 20.54 |
| Fatigue Symptom Scale: Change at Cycle 19 | -5.32 ± 27.83 | -9.01 ± 20.71 |
| Fatigue Symptom Scale: Change at Cycle 20 | -5.56 ± 26.64 | -6.53 ± 21.83 |
| Fatigue Symptom Scale: Change at Cycle 21 | -3.94 ± 25.97 | -7.41 ± 23.45 |
| Fatigue Symptom Scale: Change at Cycle 22 | -1.49 ± 25.58 | -10.64 ± 22.22 |
| Fatigue Symptom Scale: Change at Cycle 23 | -5.82 ± 25.23 | -9.60 ± 28.01 |
| Fatigue Symptom Scale: Change at Cycle 24 | -1.67 ± 27.05 | -12.50 ± 24.29 |
| Fatigue Symptom Scale: Change at Cycle 25 | -4.70 ± 26.16 | -12.35 ± 22.03 |
| Fatigue Symptom Scale: Change at Cycle 26 | -4.99 ± 24.85 | -11.46 ± 22.84 |
| Fatigue Symptom Scale: Change at Cycle 27 | -6.98 ± 23.76 | -5.36 ± 23.87 |
| Fatigue Symptom Scale: Change at Cycle 28 | -6.39 ± 18.98 | -4.70 ± 26.14 |
| Fatigue Symptom Scale: Change at PT Visit 1 | 10.02 ± 28.48 | 5.25 ± 24.00 |
| Fatigue Symptom Scale: Change at PT Visit 2 | 7.70 ± 27.65 | 9.70 ± 25.01 |
| Financial Difficulties Scale: Cycle 1 (Baseline) | 26.67 ± 30.32 | 26.21 ± 29.78 |
| Financial Difficulties Scale: Change at Cycle 2 | -0.90 ± 26.85 | -2.46 ± 25.46 |
| Financial Difficulties Scale: Change at Cycle 3 | 0.31 ± 27.62 | 0.00 ± 26.33 |
| Financial Difficulties Scale: Change at Cycle 4 | 0.89 ± 25.95 | 0.11 ± 25.10 |
| Financial Difficulties Scale: Change at Cycle 5 | 1.75 ± 27.71 | 2.58 ± 26.46 |
| Financial Difficulties Scale: Change at Cycle 6 | 1.11 ± 27.62 | 0.92 ± 26.36 |
| Financial Difficulties Scale: Change at Cycle 7 | 1.11 ± 31.08 | 0.30 ± 26.41 |
| Financial Difficulties Scale: Change at Cycle 8 | 1.15 ± 30.21 | 0.47 ± 25.27 |
| Financial Difficulties Scale: Change at Cycle 9 | 1.11 ± 29.78 | -0.51 ± 24.75 |
| Financial Difficulties Scale: Change at Cycle 10 | 0.90 ± 30.10 | -2.42 ± 24.30 |
| Financial Difficulties Scale: Change at Cycle 11 | 0.39 ± 29.37 | -0.22 ± 24.84 |
| Financial Difficulties Scale: Change at Cycle 12 | -1.05 ± 28.91 | -0.97 ± 26.39 |
| Financial Difficulties Scale: Change at Cycle 13 | -0.95 ± 28.82 | 0.30 ± 24.82 |
| Financial Difficulties Scale: Change at Cycle 14 | -1.73 ± 29.74 | -0.98 ± 25.02 |
| Financial Difficulties Scale: Change at Cycle 15 | -1.81 ± 28.96 | 1.36 ± 26.18 |
| Financial Difficulties Scale: Change at Cycle 16 | -3.16 ± 30.13 | 0.39 ± 25.97 |
| Financial Difficulties Scale: Change at Cycle 17 | -3.87 ± 29.59 | 1.35 ± 27.28 |
| Financial Difficulties Scale: Change at Cycle 18 | -2.29 ± 27.46 | 2.35 ± 26.02 |
| Financial Difficulties Scale: Change at Cycle 19 | -0.35 ± 28.41 | -0.51 ± 27.73 |
| Financial Difficulties Scale: Change at Cycle 20 | 1.19 ± 29.47 | 1.59 ± 27.71 |
| Financial Difficulties Scale: Change at Cycle 21 | 1.27 ± 28.96 | -4.94 ± 27.78 |
| Financial Difficulties Scale: Change at Cycle 22 | 2.49 ± 26.79 | -4.26 ± 23.69 |
| Financial Difficulties Scale: Change at Cycle 23 | -0.53 ± 26.43 | -2.27 ± 29.11 |
| Financial Difficulties Scale: Change at Cycle 24 | 1.11 ± 24.52 | -5.83 ± 26.03 |
| Financial Difficulties Scale: Change at Cycle 25 | 3.21 ± 27.42 | -4.63 ± 25.39 |
| Financial Difficulties Scale: Change at Cycle 26 | 2.72 ± 28.74 | -2.22 ± 26.16 |
| Financial Difficulties Scale: Change at Cycle 27 | -3.10 ± 23.92 | 1.15 ± 24.37 |
| Financial Difficulties Scale: Change at Cycle 28 | -1.67 ± 23.81 | -1.28 ± 24.00 |
| Financial Difficulties Scale: Change at PT Visit 1 | 1.70 ± 29.66 | 1.33 ± 26.21 |
| Financial Difficulties Scale: Change at PT Visit 2 | 1.98 ± 26.17 | 4.24 ± 31.32 |
| Nausea and Vomiting Scale: Cycle 1 (Baseline) | 11.14 ± 19.11 | 11.92 ± 18.76 |
| Nausea And Vomiting Scale: Change at Cycle 2 | 5.85 ± 22.65 | 4.08 ± 22.25 |
| Nausea And Vomiting Scale: Change at Cycle 3 | 5.12 ± 23.62 | 5.06 ± 21.14 |
| Nausea And Vomiting Scale: Change at Cycle 4 | 4.10 ± 21.85 | 3.56 ± 23.76 |
| Nausea And Vomiting Scale: Change at Cycle 5 | 5.13 ± 22.58 | 5.15 ± 23.81 |
| Nausea And Vomiting Scale: Change at Cycle 6 | 4.11 ± 23.36 | 2.59 ± 21.24 |
| Nausea And Vomiting Scale: Change at Cycle 7 | 2.07 ± 23.58 | 2.49 ± 22.31 |
| Nausea And Vomiting Scale: Change at Cycle 8 | -0.86 ± 20.80 | -0.77 ± 20.21 |
| Nausea And Vomiting Scale: Change at Cycle 9 | -2.54 ± 20.85 | -2.98 ± 19.78 |
| Nausea And Vomiting Scale: Change at Cycle 10 | -4.30 ± 18.81 | -2.81 ± 20.57 |
| Nausea And Vomiting Scale: Change at Cycle 11 | -3.51 ± 18.01 | -3.66 ± 20.04 |
| Nausea And Vomiting Scale: Change at Cycle 12 | -3.04 ± 18.07 | -3.45 ± 20.34 |
| Nausea And Vomiting Scale: Change at Cycle 13 | -4.02 ± 16.29 | -3.60 ± 19.25 |
| Nausea And Vomiting Scale: Change at Cycle 14 | -3.46 ± 19.54 | -5.72 ± 18.54 |
| Nausea And Vomiting Scale: Change at Cycle 15 | -3.59 ± 16.34 | -3.91 ± 16.55 |
| Nausea And Vomiting Scale: Change at Cycle 16 | -0.43 ± 20.32 | -2.55 ± 20.00 |
| Nausea And Vomiting Scale: Change at Cycle 17 | -0.60 ± 17.46 | -3.15 ± 16.48 |
| Nausea And Vomiting Scale: Change at Cycle 18 | -0.65 ± 16.90 | -3.52 ± 18.24 |
| Nausea And Vomiting Scale: Change at Cycle 19 | -0.87 ± 18.32 | -4.04 ± 19.62 |
| Nausea And Vomiting Scale: Change at Cycle 20 | -1.79 ± 18.48 | -3.97 ± 17.89 |
| Nausea And Vomiting Scale: Change at Cycle 21 | -1.05 ± 20.03 | -6.48 ± 19.80 |
| Nausea And Vomiting Scale: Change at Cycle 22 | -3.48 ± 19.14 | -8.16 ± 18.99 |
| Nausea And Vomiting Scale: Change at Cycle 23 | -4.23 ± 17.70 | -6.44 ± 24.70 |
| Nausea And Vomiting Scale: Change at Cycle 24 | -4.72 ± 16.26 | -7.92 ± 17.70 |
| Nausea And Vomiting Scale: Change at Cycle 25 | -4.17 ± 20.84 | -7.41 ± 19.29 |
| Nausea And Vomiting Scale: Change at Cycle 26 | -3.40 ± 24.29 | -9.38 ± 19.37 |
| Nausea And Vomiting Scale: Change at Cycle 27 | -5.04 ± 22.58 | -7.47 ± 20.70 |
| Nausea And Vomiting Scale: Change at Cycle 28 | -1.25 ± 20.11 | -6.41 ± 17.69 |
| Nausea and Vomiting Scale: Change at PT Visit 1 | 4.68 ± 22.20 | 4.13 ± 23.91 |
| Nausea and Vomiting Scale: Change at PT Visit 2 | 4.29 ± 23.05 | 2.73 ± 21.60 |
| Pain Symptom Scale: Cycle 1 (Baseline) | 23.92 ± 25.92 | 23.72 ± 24.82 |
| Pain Symptom Scale: Change at Cycle 2 | -6.80 ± 24.69 | -6.38 ± 23.58 |
| Pain Symptom Scale: Change at Cycle 3 | -9.89 ± 25.16 | -7.23 ± 25.78 |
| Pain Symptom Scale: Change at Cycle 4 | -10.26 ± 24.78 | -7.46 ± 26.06 |
| Pain Symptom Scale: Change at Cycle 5 | -8.86 ± 25.88 | -6.25 ± 25.42 |
| Pain Symptom Scale: Change at Cycle 6 | -8.95 ± 25.73 | -7.33 ± 24.85 |
| Pain Symptom Scale: Change at Cycle 7 | -10.95 ± 26.13 | -7.46 ± 24.79 |
| Pain Symptom Scale: Change at Cycle 8 | -9.97 ± 25.80 | -8.53 ± 22.86 |
| Pain Symptom Scale: Change at Cycle 9 | -9.29 ± 24.83 | -7.82 ± 22.98 |
| Pain Symptom Scale: Change at Cycle 10 | -9.41 ± 26.10 | -8.13 ± 22.75 |
| Pain Symptom Scale: Change at Cycle 11 | -10.33 ± 25.77 | -6.34 ± 22.97 |
| Pain Symptom Scale: Change at Cycle 12 | -10.27 ± 23.10 | -5.24 ± 25.29 |
| Pain Symptom Scale: Change at Cycle 13 | -10.28 ± 25.79 | -4.80 ± 20.27 |
| Pain Symptom Scale: Change at Cycle 14 | -10.49 ± 25.49 | -5.56 ± 23.37 |
| Pain Symptom Scale: Change at Cycle 15 | -11.15 ± 22.86 | -3.74 ± 22.77 |
| Pain Symptom Scale: Change at Cycle 16 | -9.91 ± 22.94 | -4.71 ± 23.66 |
| Pain Symptom Scale: Change at Cycle 17 | -7.59 ± 25.00 | -5.63 ± 22.63 |
| Pain Symptom Scale: Change at Cycle 18 | -8.82 ± 23.42 | -8.22 ± 20.68 |
| Pain Symptom Scale: Change at Cycle 19 | -8.16 ± 25.13 | -5.05 ± 21.48 |
| Pain Symptom Scale: Change at Cycle 20 | -6.94 ± 25.90 | -6.08 ± 19.24 |
| Pain Symptom Scale: Change at Cycle 21 | -9.92 ± 27.15 | -6.48 ± 23.44 |
| Pain Symptom Scale: Change at Cycle 22 | -7.71 ± 26.96 | -8.51 ± 19.62 |
| Pain Symptom Scale: Change at Cycle 23 | -10.85 ± 22.03 | -7.95 ± 26.29 |
| Pain Symptom Scale: Change at Cycle 24 | -10.00 ± 24.39 | -10.00 ± 17.21 |
| Pain Symptom Scale: Change at Cycle 25 | -9.94 ± 24.09 | -12.96 ± 19.96 |
| Pain Symptom Scale: Change at Cycle 26 | -10.54 ± 22.49 | -8.33 ± 18.45 |
| Pain Symptom Scale: Change at Cycle 27 | -11.24 ± 22.34 | -5.75 ± 21.95 |
| Pain Symptom Scale: Change at Cycle 28 | -10.42 ± 27.91 | -9.62 ± 19.54 |
| Pain Symptom Scale: Change at PT Visit 1 | 1.13 ± 27.27 | 2.06 ± 28.70 |
| Pain Symptom Scale: Change at PT Visit 2 | -1.49 ± 28.39 | 5.45 ± 29.96 |
| Physical Functional Scale: Cycle 1 (Baseline) | 80.86 ± 19.53 | 82.05 ± 18.32 |
| Physical Functional Scale: Change at Cycle 2 | -3.58 ± 14.56 | -3.01 ± 15.34 |
| Physical Functional Scale: Change at Cycle 3 | -2.99 ± 17.19 | -3.92 ± 17.03 |
| Physical Functional Scale: Change at Cycle 4 | -3.28 ± 18.87 | -3.50 ± 17.99 |
| Physical Functional Scale: Change at Cycle 5 | -3.10 ± 19.35 | -4.62 ± 17.62 |
| Physical Functional Scale: Change at Cycle 6 | -5.00 ± 20.30 | -3.84 ± 18.65 |
| Physical Functional Scale: Change at Cycle 7 | -3.66 ± 20.75 | -3.79 ± 19.82 |
| Physical Functional Scale: Change at Cycle 8 | -2.24 ± 21.14 | -1.56 ± 18.55 |
| Physical Functional Scale: Change at Cycle 9 | -1.59 ± 20.21 | -0.75 ± 18.44 |
| Physical Functional Scale: Change at Cycle 10 | 0.11 ± 19.93 | -0.27 ± 17.16 |
| Physical Functional Scale: Change at Cycle 11 | 0.35 ± 19.43 | 0.27 ± 17.09 |
| Physical Functional Scale: Change at Cycle 12 | -1.05 ± 20.06 | 0.89 ± 16.35 |
| Physical Functional Scale: Change at Cycle 13 | -0.80 ± 20.65 | 0.27 ± 17.41 |
| Physical Functional Scale: Change at Cycle 14 | -0.02 ± 20.14 | 1.70 ± 18.09 |
| Physical Functional Scale: Change at Cycle 15 | 0.41 ± 18.91 | -0.95 ± 17.99 |
| Physical Functional Scale: Change at Cycle 16 | -1.08 ± 19.85 | -0.08 ± 18.18 |
| Physical Functional Scale: Change at Cycle 17 | -0.46 ± 19.43 | -0.81 ± 17.55 |
| Physical Functional Scale: Change at Cycle 18 | 0.13 ± 19.74 | 0.75 ± 16.85 |
| Physical Functional Scale: Change at Cycle 19 | 1.39 ± 19.82 | 1.31 ± 14.38 |
| Physical Functional Scale: Change at Cycle 20 | 0.71 ± 21.08 | 0.85 ± 16.74 |
| Physical Functional Scale: Change at Cycle 21 | 0.42 ± 22.20 | 0.25 ± 18.18 |
| Physical Functional Scale: Change at Cycle 22 | -2.79 ± 21.90 | 1.42 ± 16.79 |
| Physical Functional Scale: Change at Cycle 23 | -1.48 ± 21.47 | 0.61 ± 19.60 |
| Physical Functional Scale: Change at Cycle 24 | -2.67 ± 22.27 | 3.00 ± 16.47 |
| Physical Functional Scale: Change at Cycle 25 | -2.18 ± 20.61 | 4.81 ± 15.91 |
| Physical Functional Scale: Change at Cycle 26 | -1.90 ± 20.09 | -1.88 ± 20.69 |
| Physical Functional Scale: Change at Cycle 27 | 0.16 ± 18.66 | -3.68 ± 19.40 |
| Physical Functional Scale: Change at Cycle 28 | -1.17 ± 17.79 | -2.82 ± 18.97 |
| Physical Functional Scale: Change at PT Visit 1 | -11.37 ± 23.67 | -7.51 ± 20.53 |
| Physical Functional Scale: Change at PT Visit 2 | -11.49 ± 24.31 | -11.82 ± 20.27 |
| Global Health Status Scale: Cycle 1 (Baseline) | 59.77 ± 22.88 | 59.90 ± 22.11 |
| Global Health Status Scale: Change at Cycle 2 | 1.81 ± 23.35 | 4.29 ± 23.42 |
| Global Health Status Scale: Change at Cycle 3 | 1.56 ± 25.05 | 2.86 ± 25.03 |
| Global Health Status Scale: Change at Cycle 4 | 1.39 ± 25.26 | 4.15 ± 23.79 |
| Global Health Status Scale: Change at Cycle 5 | 1.17 ± 25.70 | 3.92 ± 23.05 |
| Global Health Status Scale: Change at Cycle 6 | 0.68 ± 27.89 | 3.61 ± 23.13 |
| Global Health Status Scale: Change at Cycle 7 | 1.83 ± 27.81 | 3.33 ± 22.77 |
| Global Health Status Scale: Change at Cycle 8 | 3.06 ± 27.09 | 5.18 ± 23.18 |
| Global Health Status Scale: Change at Cycle 9 | 4.39 ± 26.25 | 4.68 ± 22.99 |
| Global Health Status Scale: Change at Cycle 10 | 4.80 ± 25.35 | 5.07 ± 22.77 |
| Global Health Status Scale: Change at Cycle 11 | 5.78 ± 26.62 | 3.82 ± 23.75 |
| Global Health Status Scale: Change at Cycle 12 | 3.11 ± 24.89 | 5.34 ± 24.47 |
| Global Health Status Scale: Change at Cycle 13 | 3.51 ± 23.82 | 3.83 ± 23.78 |
| Global Health Status Scale: Change at Cycle 14 | 5.97 ± 23.09 | 4.82 ± 24.86 |
| Global Health Status Scale: Change at Cycle 15 | 4.26 ± 25.98 | 1.70 ± 24.46 |
| Global Health Status Scale: Change at Cycle 16 | 3.12 ± 25.16 | 3.04 ± 23.77 |
| Global Health Status Scale: Change at Cycle 17 | 2.93 ± 24.84 | 3.83 ± 24.84 |
| Global Health Status Scale: Change at Cycle 18 | 3.02 ± 23.88 | 2.58 ± 27.08 |
| Global Health Status Scale: Change at Cycle 19 | 3.25 ± 26.39 | 3.97 ± 25.43 |
| Global Health Status Scale: Change at Cycle 20 | 5.12 ± 24.20 | 4.89 ± 25.69 |
| Global Health Status Scale: Change at Cycle 21 | 5.38 ± 23.87 | 5.40 ± 24.72 |
| Global Health Status Scale: Change at Cycle 22 | 3.79 ± 22.56 | 3.19 ± 25.57 |
| Global Health Status Scale: Change at Cycle 23 | 4.03 ± 23.85 | 4.07 ± 27.18 |
| Global Health Status Scale: Change at Cycle 24 | 4.24 ± 22.66 | 2.92 ± 30.58 |
| Global Health Status Scale: Change at Cycle 25 | 3.59 ± 22.38 | 8.10 ± 25.39 |
| Global Health Status Scale: Change at Cycle 26 | 7.27 ± 24.55 | 5.47 ± 26.91 |
| Global Health Status Scale: Change at Cycle 27 | 7.54 ± 23.19 | 1.72 ± 28.38 |
| Global Health Status Scale: Change at Cycle 28 | 4.49 ± 22.69 | 4.81 ± 28.98 |
| Global Health Status Scale: Change at PT Visit 1 | -7.24 ± 27.24 | -6.14 ± 24.97 |
| Global Health Status Scale: Change at PT Visit 2 | -2.72 ± 27.46 | -5.68 ± 26.57 |
| Role Functional Scale: Cycle 1 (Baseline) | 77.06 ± 27.02 | 79.33 ± 25.12 |
| Role Functional Scale: Change at Cycle 2 | -3.78 ± 24.99 | -2.82 ± 24.35 |
| Role Functional Scale: Change at Cycle 3 | -3.62 ± 25.96 | -4.55 ± 28.00 |
| Role Functional Scale: Change at Cycle 4 | -4.64 ± 27.69 | -5.99 ± 26.87 |
| Role Functional Scale: Change at Cycle 5 | -4.72 ± 27.68 | -7.41 ± 27.25 |
| Role Functional Scale: Change at Cycle 6 | -6.13 ± 28.94 | -6.03 ± 28.51 |
| Role Functional Scale: Change at Cycle 7 | -4.82 ± 29.75 | -5.34 ± 26.31 |
| Role Functional Scale: Change at Cycle 8 | -1.85 ± 28.87 | -2.38 ± 26.41 |
| Role Functional Scale: Change at Cycle 9 | -1.19 ± 28.57 | -2.47 ± 27.29 |
| Role Functional Scale: Change at Cycle 10 | -1.79 ± 28.10 | 0.90 ± 25.97 |
| Role Functional Scale: Change at Cycle 11 | -0.78 ± 28.34 | -2.69 ± 24.94 |
| Role Functional Scale: Change at Cycle 12 | -1.05 ± 27.28 | 0.24 ± 24.07 |
| Role Functional Scale: Change at Cycle 13 | -2.01 ± 26.61 | -2.40 ± 24.91 |
| Role Functional Scale: Change at Cycle 14 | -0.86 ± 27.27 | -1.31 ± 25.66 |
| Role Functional Scale: Change at Cycle 15 | -1.03 ± 27.51 | -3.23 ± 25.40 |
| Role Functional Scale: Change at Cycle 16 | -3.16 ± 28.73 | -2.35 ± 25.48 |
| Role Functional Scale: Change at Cycle 17 | -1.04 ± 26.69 | -3.38 ± 25.88 |
| Role Functional Scale: Change at Cycle 18 | -0.16 ± 27.10 | 0.23 ± 26.05 |
| Role Functional Scale: Change at Cycle 19 | 1.04 ± 27.55 | -0.25 ± 23.48 |
| Role Functional Scale: Change at Cycle 20 | -1.19 ± 30.04 | 0.79 ± 23.46 |
| Role Functional Scale: Change at Cycle 21 | -0.84 ± 28.98 | 0.00 ± 27.47 |
| Role Functional Scale: Change at Cycle 22 | -2.24 ± 27.96 | 1.06 ± 22.63 |
| Role Functional Scale: Change at Cycle 23 | -3.44 ± 30.11 | 1.14 ± 25.01 |
| Role Functional Scale: Change at Cycle 24 | -4.44 ± 29.73 | 2.08 ± 24.22 |
| Role Functional Scale: Change at Cycle 25 | -3.53 ± 29.21 | 4.63 ± 26.91 |
| Role Functional Scale: Change at Cycle 26 | -1.36 ± 28.02 | 0.52 ± 26.60 |
| Role Functional Scale: Change at Cycle 27 | -1.55 ± 30.82 | -4.02 ± 29.77 |
| Role Functional Scale: Change at Cycle 28 | -0.42 ± 27.86 | -3.85 ± 29.56 |
| Role Functional Scale: Change at PT Visit 1 | -14.61 ± 30.41 | -9.49 ± 28.64 |
| Role Functional Scale: Change at PT Visit 2 | -10.73 ± 31.94 | -15.45 ± 31.82 |
| Social Functional Scale: Cycle 1 (Baseline) | 77.96 ± 24.09 | 75.90 ± 24.69 |
| Social Functional Scale: Change at Cycle 2 | -3.45 ± 24.07 | -0.44 ± 23.09 |
| Social Functional Scale: Change at Cycle 3 | -4.62 ± 25.25 | -2.07 ± 25.35 |
| Social Functional Scale: Change at Cycle 4 | -2.59 ± 25.08 | -1.70 ± 26.58 |
| Social Functional Scale: Change at Cycle 5 | -5.54 ± 27.03 | -3.26 ± 27.24 |
| Social Functional Scale: Change at Cycle 6 | -5.72 ± 27.87 | -1.04 ± 27.20 |
| Social Functional Scale: Change at Cycle 7 | -2.69 ± 27.13 | -0.15 ± 26.00 |
| Social Functional Scale: Change at Cycle 8 | -1.72 ± 26.93 | 1.08 ± 26.49 |
| Social Functional Scale: Change at Cycle 9 | 0.56 ± 27.59 | 0.77 ± 25.11 |
| Social Functional Scale: Change at Cycle 10 | -0.81 ± 27.31 | 2.31 ± 25.75 |
| Social Functional Scale: Change at Cycle 11 | 0.58 ± 27.35 | 1.94 ± 24.39 |
| Social Functional Scale: Change at Cycle 12 | 0.52 ± 28.59 | 2.40 ± 24.70 |
| Social Functional Scale: Change at Cycle 13 | 0.83 ± 25.31 | 2.10 ± 25.73 |
| Social Functional Scale: Change at Cycle 14 | 1.98 ± 26.71 | 2.12 ± 24.89 |
| Social Functional Scale: Change at Cycle 15 | 1.79 ± 27.24 | 0.00 ± 27.08 |
| Social Functional Scale: Change at Cycle 16 | -0.72 ± 25.76 | 0.39 ± 25.84 |
| Social Functional Scale: Change at Cycle 17 | -0.45 ± 26.51 | 1.58 ± 24.39 |
| Social Functional Scale: Change at Cycle 18 | -0.98 ± 25.99 | 2.11 ± 26.42 |
| Social Functional Scale: Change at Cycle 19 | 2.26 ± 26.56 | 3.28 ± 21.53 |
| Social Functional Scale: Change at Cycle 20 | 1.59 ± 27.09 | 0.79 ± 22.88 |
| Social Functional Scale: Change at Cycle 21 | 1.27 ± 28.09 | 5.86 ± 22.00 |
| Social Functional Scale: Change at Cycle 22 | 1.24 ± 27.72 | 2.84 ± 24.16 |
| Social Functional Scale: Change at Cycle 23 | 6.08 ± 27.32 | 1.89 ± 22.51 |
| Social Functional Scale: Change at Cycle 24 | 5.83 ± 25.64 | 4.17 ± 24.39 |
| Social Functional Scale: Change at Cycle 25 | 1.60 ± 27.27 | 2.78 ± 23.40 |
| Social Functional Scale: Change at Cycle 26 | 3.74 ± 26.19 | 1.56 ± 24.45 |
| Social Functional Scale: Change at Cycle 27 | 5.81 ± 24.37 | -1.72 ± 26.85 |
| Social Functional Scale: Change at Cycle 28 | 6.25 ± 23.48 | -0.64 ± 24.26 |
| Social Functional Scale: Change at PT Visit 1 | -9.13 ± 26.47 | -3.80 ± 28.74 |
| Social Functional Scale: Change at PT Visit 2 | -5.45 ± 28.49 | -8.48 ± 28.98 |
| Insomnia Symptom Scale: Cycle 1 (Baseline) | 22.94 ± 28.00 | 25.41 ± 28.81 |
| Insomnia Symptom Scale: Change at Cycle 2 | -0.69 ± 26.82 | -0.39 ± 28.27 |
| Insomnia Symptom Scale: Change at Cycle 3 | -3.53 ± 27.03 | -3.48 ± 30.14 |
| Insomnia Symptom Scale: Change at Cycle 4 | -2.88 ± 28.14 | -3.62 ± 30.40 |
| Insomnia Symptom Scale: Change at Cycle 5 | -2.21 ± 29.27 | -2.66 ± 30.17 |
| Insomnia Symptom Scale: Change at Cycle 6 | -2.94 ± 28.63 | -5.58 ± 32.53 |
| Insomnia Symptom Scale: Change at Cycle 7 | -4.56 ± 28.42 | -4.82 ± 32.98 |
| Insomnia Symptom Scale: Change at Cycle 8 | -6.13 ± 27.72 | -6.45 ± 30.75 |
| Insomnia Symptom Scale: Change at Cycle 9 | -8.97 ± 25.69 | -6.12 ± 30.32 |
| Insomnia Symptom Scale: Change at Cycle 10 | -8.24 ± 26.69 | -4.42 ± 28.79 |
| Insomnia Symptom Scale: Change at Cycle 11 | -8.97 ± 28.19 | -5.81 ± 27.69 |
| Insomnia Symptom Scale: Change at Cycle 12 | -8.81 ± 27.67 | -6.43 ± 26.49 |
| Insomnia Symptom Scale: Change at Cycle 13 | -10.17 ± 26.71 | -5.11 ± 24.29 |
| Insomnia Symptom Scale: Change at Cycle 14 | -9.14 ± 26.84 | -7.84 ± 24.45 |
| Insomnia Symptom Scale: Change at Cycle 15 | -9.74 ± 28.89 | -5.10 ± 21.59 |
| Insomnia Symptom Scale: Change at Cycle 16 | -8.91 ± 26.14 | -4.31 ± 26.62 |
| Insomnia Symptom Scale: Change at Cycle 17 | -11.01 ± 26.62 | -5.41 ± 26.48 |
| Insomnia Symptom Scale: Change at Cycle 18 | -8.82 ± 28.12 | -8.45 ± 20.09 |
| Insomnia Symptom Scale: Change at Cycle 19 | -11.46 ± 29.35 | -7.58 ± 22.49 |
| Insomnia Symptom Scale: Change at Cycle 20 | -10.32 ± 27.37 | -5.29 ± 25.55 |
| Insomnia Symptom Scale: Change at Cycle 21 | -11.81 ± 27.24 | -4.94 ± 27.02 |
| Insomnia Symptom Scale: Change at Cycle 22 | -10.95 ± 31.46 | -7.80 ± 19.92 |
| Insomnia Symptom Scale: Change at Cycle 23 | -10.58 ± 34.82 | -6.06 ± 23.04 |
| Insomnia Symptom Scale: Change at Cycle 24 | -9.44 ± 31.94 | -7.50 ± 21.99 |
| Insomnia Symptom Scale: Change at Cycle 25 | -10.26 ± 28.42 | -8.33 ± 26.87 |
| Insomnia Symptom Scale: Change at Cycle 26 | -9.52 ± 32.63 | -4.17 ± 20.30 |
| Insomnia Symptom Scale: Change at Cycle 27 | -13.18 ± 30.11 | -4.60 ± 19.36 |
| Insomnia Symptom Scale: Change at Cycle 28 | -11.67 ± 31.62 | -1.28 ± 22.07 |
| Insomnia Symptom Scale: Change at PT Visit 1 | 2.81 ± 29.19 | -1.32 ± 30.81 |
| Insomnia Symptom Scale: Change at PT Visit 2 | 5.67 ± 29.23 | 3.03 ± 31.13 |
The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).
| score on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Anxiety: Cycle 1 (Baseline) | 40.10 ± 25.85 | 40.48 ± 25.32 |
| Anxiety: Change at Cycle 2 | -2.58 ± 21.72 | -4.11 ± 21.19 |
| Anxiety: Change at Cycle 3 | -4.14 ± 22.45 | -3.87 ± 23.19 |
| Anxiety: Change at Cycle 4 | -4.52 ± 23.01 | -7.25 ± 23.16 |
| Anxiety: Change at Cycle 5 | -4.10 ± 22.94 | -7.39 ± 24.36 |
| Anxiety: Change at Cycle 6 | -4.54 ± 23.97 | -8.42 ± 25.21 |
| Anxiety: Change at Cycle 7 | -6.40 ± 24.00 | -10.40 ± 24.37 |
| Anxiety: Change at Cycle 8 | -9.00 ± 23.17 | -11.92 ± 24.50 |
| Anxiety: Change at Cycle 9 | -10.09 ± 23.30 | -11.43 ± 23.24 |
| Anxiety: Change at Cycle 10 | -11.17 ± 25.05 | -12.64 ± 22.09 |
| Anxiety: Change at Cycle 11 | -10.78 ± 23.47 | -12.09 ± 21.84 |
| Anxiety: Change at Cycle 12 | -12.62 ± 26.24 | -13.16 ± 23.11 |
| Anxiety: Change at Cycle 13 | -13.32 ± 25.93 | -13.33 ± 22.47 |
| Anxiety: Change at Cycle 14 | -14.32 ± 26.49 | -12.43 ± 23.59 |
| Anxiety: Change at Cycle 15 | -13.42 ± 26.64 | -10.65 ± 25.74 |
| Anxiety: Change at Cycle 16 | -12.75 ± 26.87 | -12.57 ± 23.89 |
| Anxiety: Change at Cycle 17 | -13.41 ± 27.30 | -12.79 ± 21.01 |
| Anxiety: Change at Cycle 18 | -13.53 ± 28.05 | -12.38 ± 22.90 |
| Anxiety: Change at Cycle 19 | -14.50 ± 27.41 | -12.48 ± 20.08 |
| Anxiety: Change at Cycle 20 | -15.34 ± 29.21 | -12.37 ± 23.73 |
| Anxiety: Change at Cycle 21 | -16.03 ± 28.84 | -14.47 ± 25.00 |
| Anxiety: Change at Cycle 22 | -13.30 ± 30.77 | -15.46 ± 23.83 |
| Anxiety: Change at Cycle 23 | -17.28 ± 30.64 | -14.47 ± 29.55 |
| Anxiety: Change at Cycle 24 | -16.11 ± 30.65 | -17.09 ± 23.76 |
| Anxiety: Change at Cycle 25 | -16.03 ± 29.47 | -17.78 ± 23.68 |
| Anxiety: Change at Cycle 26 | -19.73 ± 30.28 | -13.26 ± 22.11 |
| Anxiety: Change at Cycle 27 | -21.71 ± 29.89 | -12.70 ± 20.67 |
| Anxiety: Change at Cycle 28 | -22.51 ± 29.34 | -12.89 ± 22.38 |
| Anxiety: Change at PT Visit 1 | -0.73 ± 25.18 | -4.73 ± 27.21 |
| Anxiety: Change at PT Visit 2 | -4.04 ± 28.24 | -3.98 ± 25.02 |
| Body Image: Cycle 1 (Baseline) | 23.53 ± 28.40 | 23.68 ± 27.47 |
| Body Image: Change at Cycle 2 | 1.33 ± 28.19 | 1.20 ± 26.44 |
| Body Image: Change at Cycle 3 | 1.48 ± 29.06 | 3.88 ± 28.03 |
| Body Image: Change at Cycle 4 | 4.20 ± 28.51 | 1.15 ± 27.19 |
| Body Image: Change at Cycle 5 | 2.86 ± 30.91 | 1.06 ± 25.74 |
| Body Image: Change at Cycle 6 | 0.75 ± 30.11 | 2.78 ± 28.48 |
| Body Image: Change at Cycle 7 | -0.56 ± 28.94 | 0.29 ± 25.53 |
| Body Image: Change at Cycle 8 | -1.74 ± 29.83 | 0.00 ± 26.30 |
| Body Image: Change at Cycle 9 | -3.58 ± 28.74 | -0.69 ± 24.52 |
| Body Image: Change at Cycle 10 | -5.07 ± 30.15 | -3.25 ± 24.55 |
| Body Image: Change at Cycle 11 | -4.62 ± 30.24 | -1.53 ± 25.46 |
| Body Image: Change at Cycle 12 | -5.31 ± 31.92 | -2.66 ± 27.04 |
| Body Image: Change at Cycle 13 | -4.73 ± 30.23 | -2.73 ± 25.99 |
| Body Image: Change at Cycle 14 | -5.43 ± 29.70 | -4.62 ± 24.05 |
| Body Image: Change at Cycle 15 | -3.08 ± 30.63 | -2.43 ± 27.03 |
| Body Image: Change at Cycle 16 | -1.74 ± 32.99 | -1.19 ± 26.10 |
| Body Image: Change at Cycle 17 | -2.70 ± 32.76 | -2.28 ± 21.75 |
| Body Image: Change at Cycle 18 | -2.64 ± 30.44 | -5.71 ± 23.38 |
| Body Image: Change at Cycle 19 | -2.81 ± 33.57 | -5.21 ± 20.76 |
| Body Image: Change at Cycle 20 | -3.97 ± 30.79 | -5.38 ± 22.74 |
| Body Image: Change at Cycle 21 | 1.69 ± 30.15 | -8.18 ± 26.07 |
| Body Image: Change at Cycle 22 | -1.49 ± 32.01 | -10.87 ± 22.28 |
| Body Image: Change at Cycle 23 | -5.82 ± 24.35 | -8.53 ± 29.18 |
| Body Image: Change at Cycle 24 | -0.56 ± 31.25 | -11.11 ± 23.36 |
| Body Image: Change at Cycle 25 | -3.21 ± 28.97 | -11.43 ± 24.18 |
| Body Image: Change at Cycle 26 | -4.76 ± 29.66 | -6.45 ± 18.09 |
| Body Image: Change at Cycle 27 | 0.78 ± 24.65 | -7.14 ± 21.00 |
| Body Image: Change at Cycle 28 | -4.27 ± 26.69 | -4.00 ± 24.19 |
| Body Image: Change at PT Visit 1 | 2.48 ± 31.57 | 3.42 ± 29.31 |
| Body Image: Change at PT Visit 2 | 2.36 ± 35.40 | 6.35 ± 27.38 |
| Dry Mouth: Cycle 1 (Baseline) | 21.80 ± 25.07 | 23.32 ± 26.79 |
| Dry Mouth: Change at Cycle 2 | 7.72 ± 28.70 | 3.00 ± 25.43 |
| Dry Mouth: Change at Cycle 3 | 6.10 ± 28.65 | 4.87 ± 27.33 |
| Dry Mouth: Change at Cycle 4 | 4.76 ± 29.40 | 2.66 ± 31.06 |
| Dry Mouth: Change at Cycle 5 | 2.47 ± 29.67 | 2.57 ± 28.68 |
| Dry Mouth: Change at Cycle 6 | 2.96 ± 30.14 | 1.19 ± 27.65 |
| Dry Mouth: Change at Cycle 7 | -1.96 ± 28.82 | 0.44 ± 28.54 |
| Dry Mouth: Change at Cycle 8 | -2.43 ± 28.68 | -2.66 ± 26.27 |
| Dry Mouth: Change at Cycle 9 | -3.70 ± 25.70 | -4.32 ± 24.74 |
| Dry Mouth: Change at Cycle 10 | -6.27 ± 25.04 | -3.46 ± 23.53 |
| Dry Mouth: Change at Cycle 11 | -7.69 ± 25.46 | -1.96 ± 26.56 |
| Dry Mouth: Change at Cycle 12 | -8.18 ± 24.22 | -4.35 ± 26.36 |
| Dry Mouth: Change at Cycle 13 | -9.69 ± 24.08 | -8.48 ± 26.50 |
| Dry Mouth: Change at Cycle 14 | -8.33 ± 24.60 | -3.63 ± 29.78 |
| Dry Mouth: Change at Cycle 15 | -7.89 ± 22.20 | -7.29 ± 26.58 |
| Dry Mouth: Change at Cycle 16 | -6.32 ± 24.44 | -8.33 ± 27.80 |
| Dry Mouth: Change at Cycle 17 | -7.44 ± 23.12 | -3.20 ± 24.32 |
| Dry Mouth: Change at Cycle 18 | -5.56 ± 24.86 | -8.10 ± 28.62 |
| Dry Mouth: Change at Cycle 19 | -5.90 ± 24.18 | -7.69 ± 25.53 |
| Dry Mouth: Change at Cycle 20 | -6.35 ± 26.62 | -9.68 ± 27.25 |
| Dry Mouth: Change at Cycle 21 | -7.17 ± 24.27 | -9.43 ± 20.02 |
| Dry Mouth: Change at Cycle 22 | -3.98 ± 26.29 | -8.70 ± 23.76 |
| Dry Mouth: Change at Cycle 23 | -7.94 ± 23.73 | -3.88 ± 25.42 |
| Dry Mouth: Change at Cycle 24 | -6.67 ± 25.15 | -9.40 ± 28.56 |
| Dry Mouth: Change at Cycle 25 | -8.33 ± 22.75 | -9.52 ± 28.66 |
| Dry Mouth: Change at Cycle 26 | -2.72 ± 23.41 | -7.53 ± 26.82 |
| Dry Mouth: Change at Cycle 27 | -6.98 ± 21.28 | -7.14 ± 27.75 |
| Dry Mouth: Change at Cycle 28 | -8.55 ± 21.24 | -8.00 ± 22.11 |
| Dry Mouth: Change at PT Visit 1 | 0.19 ± 28.70 | 2.38 ± 31.58 |
| Dry Mouth: Change at PT Visit 2 | -1.35 ± 30.09 | 1.89 ± 25.95 |
| Dysphagia: Cycle 1 (Baseline) | 16.29 ± 21.46 | 14.15 ± 18.93 |
| Dysphagia: Change at Cycle 2 | -2.27 ± 17.64 | -0.53 ± 19.32 |
| Dysphagia: Change at Cycle 3 | -3.39 ± 18.57 | -2.15 ± 19.67 |
| Dysphagia: Change at Cycle 4 | -2.94 ± 18.93 | -1.08 ± 18.79 |
| Dysphagia: Change at Cycle 5 | -3.22 ± 19.92 | -1.83 ± 18.99 |
| Dysphagia: Change at Cycle 6 | -4.20 ± 18.99 | -2.25 ± 18.70 |
| Dysphagia: Change at Cycle 7 | -4.83 ± 20.56 | -1.97 ± 19.94 |
| Dysphagia: Change at Cycle 8 | -5.96 ± 18.80 | -3.29 ± 18.48 |
| Dysphagia: Change at Cycle 9 | -6.17 ± 18.21 | -3.86 ± 18.49 |
| Dysphagia: Change at Cycle 10 | -6.03 ± 17.37 | -4.61 ± 16.87 |
| Dysphagia: Change at Cycle 11 | -6.25 ± 17.09 | -2.83 ± 17.03 |
| Dysphagia: Change at Cycle 12 | -7.06 ± 17.65 | -4.19 ± 15.84 |
| Dysphagia: Change at Cycle 13 | -6.93 ± 18.71 | -3.54 ± 17.61 |
| Dysphagia: Change at Cycle 14 | -8.01 ± 18.53 | -4.95 ± 18.22 |
| Dysphagia: Change at Cycle 15 | -6.45 ± 17.38 | -2.14 ± 18.69 |
| Dysphagia: Change at Cycle 16 | -4.41 ± 18.29 | -3.70 ± 21.08 |
| Dysphagia: Change at Cycle 17 | -5.36 ± 16.87 | -3.20 ± 14.99 |
| Dysphagia: Change at Cycle 18 | -4.90 ± 16.44 | -3.33 ± 19.78 |
| Dysphagia: Change at Cycle 19 | -4.40 ± 17.10 | -3.59 ± 14.31 |
| Dysphagia: Change at Cycle 20 | -2.51 ± 16.21 | -3.76 ± 15.83 |
| Dysphagia: Change at Cycle 21 | -3.80 ± 19.24 | -2.10 ± 17.84 |
| Dysphagia: Change at Cycle 22 | -3.65 ± 20.41 | -4.83 ± 15.65 |
| Dysphagia: Change at Cycle 23 | -4.23 ± 18.87 | -3.88 ± 17.63 |
| Dysphagia: Change at Cycle 24 | -5.00 ± 18.35 | -3.70 ± 13.08 |
| Dysphagia: Change at Cycle 25 | -5.98 ± 19.61 | -2.22 ± 16.79 |
| Dysphagia: Change at Cycle 26 | -5.67 ± 20.43 | -2.87 ± 16.22 |
| Dysphagia: Change at Cycle 27 | -5.68 ± 20.91 | -4.37 ± 12.22 |
| Dysphagia: Change at Cycle 28 | -8.26 ± 19.86 | -3.56 ± 11.44 |
| Dysphagia: Change at PT Visit 1 | 0.44 ± 24.15 | 2.83 ± 22.63 |
| Dysphagia: Change at PT Visit 2 | -2.81 ± 24.40 | 3.25 ± 19.81 |
| Eating Restrictions: Cycle 1 (Baseline) | 23.26 ± 21.78 | 22.33 ± 20.22 |
| Eating Restrictions: Change at Cycle 2 | -1.41 ± 19.36 | -1.54 ± 19.62 |
| Eating Restrictions: Change at Cycle 3 | -1.04 ± 21.09 | -2.20 ± 20.94 |
| Eating Restrictions: Change at Cycle 4 | -2.24 ± 20.81 | -1.39 ± 23.36 |
| Eating Restrictions: Change at Cycle 5 | -1.39 ± 22.10 | -0.09 ± 23.31 |
| Eating Restrictions: Change at Cycle 6 | -1.35 ± 22.77 | -3.32 ± 23.14 |
| Eating Restrictions: Change at Cycle 7 | -2.45 ± 22.68 | -2.67 ± 21.66 |
| Eating Restrictions: Change at Cycle 8 | -4.29 ± 22.70 | -5.56 ± 19.87 |
| Eating Restrictions: Change at Cycle 9 | -6.99 ± 21.16 | -6.48 ± 19.69 |
| Eating Restrictions: Change at Cycle 10 | -7.06 ± 21.32 | -5.89 ± 19.30 |
| Eating Restrictions: Change at Cycle 11 | -8.22 ± 21.25 | -5.05 ± 19.98 |
| Eating Restrictions: Change at Cycle 12 | -7.74 ± 21.16 | -6.34 ± 19.87 |
| Eating Restrictions: Change at Cycle 13 | -8.55 ± 20.41 | -8.41 ± 19.57 |
| Eating Restrictions: Change at Cycle 14 | -8.62 ± 19.16 | -8.58 ± 21.16 |
| Eating Restrictions: Change at Cycle 15 | -6.85 ± 20.92 | -5.56 ± 21.21 |
| Eating Restrictions: Change at Cycle 16 | -5.77 ± 22.01 | -6.94 ± 20.36 |
| Eating Restrictions: Change at Cycle 17 | -5.56 ± 21.95 | -7.42 ± 17.76 |
| Eating Restrictions: Change at Cycle 18 | -7.27 ± 20.40 | -6.90 ± 21.14 |
| Eating Restrictions: Change at Cycle 19 | -7.03 ± 21.78 | -5.38 ± 18.07 |
| Eating Restrictions: Change at Cycle 20 | -4.56 ± 21.03 | -4.44 ± 16.72 |
| Eating Restrictions: Change at Cycle 21 | -5.80 ± 22.58 | -5.03 ± 19.97 |
| Eating Restrictions: Change at Cycle 22 | -3.65 ± 21.79 | -6.16 ± 16.80 |
| Eating Restrictions: Change at Cycle 23 | -3.70 ± 22.74 | -5.23 ± 20.25 |
| Eating Restrictions: Change at Cycle 24 | -5.00 ± 20.77 | -7.91 ± 15.76 |
| Eating Restrictions: Change at Cycle 25 | -5.77 ± 21.10 | -5.95 ± 16.61 |
| Eating Restrictions: Change at Cycle 26 | -6.80 ± 21.22 | -2.42 ± 22.89 |
| Eating Restrictions: Change at Cycle 27 | -5.62 ± 23.48 | -3.87 ± 10.26 |
| Eating Restrictions: Change at Cycle 28 | -7.91 ± 21.79 | -5.00 ± 11.02 |
| Eating Restrictions: Change at PT Visit 1 | 1.52 ± 24.48 | 0.94 ± 24.70 |
| Eating Restrictions: Change at PT Visit 2 | -2.10 ± 25.32 | 0.94 ± 21.46 |
| Hair Loss: Cycle 1 (Baseline) | 4.73 ± 13.28 | 4.04 ± 13.20 |
| Hair Loss: Change at Cycle 2 | 0.20 ± 14.85 | 1.27 ± 16.59 |
| Hair Loss: Change at Cycle 3 | 4.34 ± 17.51 | 4.52 ± 18.71 |
| Hair Loss: Change at Cycle 4 | 5.40 ± 18.46 | 6.53 ± 20.99 |
| Hair Loss: Change at Cycle 5 | 6.12 ± 19.38 | 7.18 ± 19.49 |
| Hair Loss: Change at Cycle 6 | 6.93 ± 18.87 | 10.07 ± 22.94 |
| Hair Loss: Change at Cycle 7 | 5.72 ± 19.91 | 9.26 ± 22.92 |
| Hair Loss: Change at Cycle 8 | 5.00 ± 18.96 | 7.38 ± 23.05 |
| Hair Loss: Change at Cycle 9 | 2.38 ± 17.43 | 6.46 ± 21.06 |
| Hair Loss: Change at Cycle 10 | 0.64 ± 16.88 | 4.22 ± 19.51 |
| Hair Loss: Change at Cycle 11 | -0.10 ± 17.02 | 2.54 ± 17.51 |
| Hair Loss: Change at Cycle 12 | 0.21 ± 19.70 | 1.96 ± 15.72 |
| Hair Loss: Change at Cycle 13 | 0.36 ± 18.91 | 2.29 ± 15.46 |
| Hair Loss: Change at Cycle 14 | -1.37 ± 17.59 | 1.83 ± 15.15 |
| Hair Loss: Change at Cycle 15 | -0.39 ± 15.65 | 1.58 ± 12.65 |
| Hair Loss: Change at Cycle 16 | -1.47 ± 17.47 | 1.42 ± 13.91 |
| Hair Loss: Change at Cycle 17 | -1.07 ± 17.75 | 0.23 ± 12.57 |
| Hair Loss: Change at Cycle 18 | -1.68 ± 17.58 | -0.71 ± 13.14 |
| Hair Loss: Change at Cycle 19 | -0.90 ± 18.12 | 0.51 ± 14.12 |
| Hair Loss: Change at Cycle 20 | -0.20 ± 19.21 | -1.61 ± 12.70 |
| Hair Loss: Change at Cycle 21 | -1.07 ± 19.43 | -1.57 ± 8.81 |
| Hair Loss: Change at Cycle 22 | -0.50 ± 16.66 | -3.26 ± 11.98 |
| Hair Loss: Change at Cycle 23 | -0.54 ± 16.79 | -1.19 ± 11.28 |
| Hair Loss: Change at Cycle 24 | -1.39 ± 17.44 | 1.71 ± 16.13 |
| Hair Loss: Change at Cycle 25 | -1.96 ± 18.75 | -0.95 ± 9.85 |
| Hair Loss: Change at Cycle 26 | -1.02 ± 19.37 | -0.54 ± 10.08 |
| Hair Loss: Change at Cycle 27 | -3.10 ± 15.96 | -0.60 ± 10.62 |
| Hair Loss: Change at Cycle 28 | -4.70 ± 20.57 | -1.33 ± 10.67 |
| Hair Loss: Change at PT Visit 1 | 4.98 ± 19.73 | 4.51 ± 20.39 |
| Hair Loss: Change at PT Visit 2 | 15.82 ± 25.35 | 22.22 ± 30.81 |
| Pain: Cycle 1 (Baseline) | 26.48 ± 21.34 | 26.47 ± 20.70 |
| Pain: Change at Cycle 2 | -4.63 ± 20.30 | -5.86 ± 19.15 |
| Pain: Change at Cycle 3 | -6.96 ± 20.37 | -5.86 ± 20.68 |
| Pain: Change at Cycle 4 | -6.45 ± 21.47 | -7.48 ± 21.23 |
| Pain: Change at Cycle 5 | -7.28 ± 20.95 | -6.89 ± 22.10 |
| Pain: Change at Cycle 6 | -7.24 ± 20.84 | -7.22 ± 21.62 |
| Pain: Change at Cycle 7 | -9.52 ± 21.18 | -6.62 ± 21.63 |
| Pain: Change at Cycle 8 | -10.53 ± 21.62 | -8.16 ± 20.11 |
| Pain: Change at Cycle 9 | -10.08 ± 19.60 | -8.98 ± 20.29 |
| Pain: Change at Cycle 10 | -10.63 ± 19.23 | -8.59 ± 20.38 |
| Pain: Change at Cycle 11 | -11.65 ± 19.35 | -8.01 ± 18.97 |
| Pain: Change at Cycle 12 | -11.76 ± 19.87 | -7.19 ± 19.11 |
| Pain: Change at Cycle 13 | -11.92 ± 18.93 | -9.24 ± 19.79 |
| Pain: Change at Cycle 14 | -11.66 ± 19.51 | -9.82 ± 19.91 |
| Pain: Change at Cycle 15 | -11.15 ± 18.16 | -8.51 ± 20.94 |
| Pain: Change at Cycle 16 | -8.72 ± 18.02 | -10.52 ± 21.30 |
| Pain: Change at Cycle 17 | -8.88 ± 18.17 | -9.93 ± 17.27 |
| Pain: Change at Cycle 18 | -8.31 ± 18.33 | -11.19 ± 18.16 |
| Pain: Change at Cycle 19 | -6.63 ± 17.25 | -10.38 ± 14.51 |
| Pain: Change at Cycle 20 | -5.72 ± 19.98 | -10.35 ± 16.65 |
| Pain: Change at Cycle 21 | -8.19 ± 18.27 | -7.55 ± 16.77 |
| Pain: Change at Cycle 22 | -9.08 ± 18.10 | -9.42 ± 16.72 |
| Pain: Change at Cycle 23 | -9.66 ± 20.75 | -8.53 ± 19.96 |
| Pain: Change at Cycle 24 | -9.86 ± 21.56 | -8.76 ± 15.53 |
| Pain: Change at Cycle 25 | -10.58 ± 19.88 | -8.10 ± 18.69 |
| Pain: Change at Cycle 26 | -9.01 ± 17.99 | -9.41 ± 17.58 |
| Pain: Change at Cycle 27 | -12.02 ± 17.28 | -9.23 ± 14.58 |
| Pain: Change at Cycle 28 | -11.54 ± 18.20 | -7.33 ± 13.46 |
| Pain: Change at PT Visit 1 | -1.70 ± 23.07 | -2.99 ± 23.86 |
| Pain: Change at PT Visit 2 | -7.49 ± 24.09 | -0.03 ± 22.04 |
| Reflux Symptoms: Cycle 1 (Baseline) | 16.68 ± 19.03 | 17.34 ± 18.31 |
| Reflux Symptoms: Change at Cycle 2 | -0.13 ± 16.33 | -1.99 ± 18.03 |
| Reflux Symptoms: Change at Cycle 3 | -0.52 ± 18.95 | -2.28 ± 19.53 |
| Reflux Symptoms: Change at Cycle 4 | -0.98 ± 19.18 | -1.90 ± 19.93 |
| Reflux Symptoms: Change at Cycle 5 | -1.92 ± 18.98 | -1.72 ± 20.10 |
| Reflux Symptoms: Change at Cycle 6 | -2.90 ± 20.42 | -3.59 ± 19.04 |
| Reflux Symptoms: Change at Cycle 7 | -4.18 ± 18.36 | -3.20 ± 20.21 |
| Reflux Symptoms: Change at Cycle 8 | -4.96 ± 19.39 | -5.74 ± 19.53 |
| Reflux Symptoms: Change at Cycle 9 | -5.02 ± 18.97 | -5.18 ± 19.81 |
| Reflux Symptoms: Change at Cycle 10 | -6.12 ± 17.81 | -6.48 ± 18.55 |
| Reflux Symptoms: Change at Cycle 11 | -6.44 ± 18.74 | -6.03 ± 18.07 |
| Reflux Symptoms: Change at Cycle 12 | -4.82 ± 18.00 | -7.49 ± 16.99 |
| Reflux Symptoms: Change at Cycle 13 | -6.42 ± 17.09 | -6.77 ± 18.19 |
| Reflux Symptoms: Change at Cycle 14 | -5.39 ± 18.24 | -7.37 ± 17.45 |
| Reflux Symptoms: Change at Cycle 15 | -5.00 ± 16.66 | -4.98 ± 18.72 |
| Reflux Symptoms: Change at Cycle 16 | -3.07 ± 18.39 | -4.89 ± 22.31 |
| Reflux Symptoms: Change at Cycle 17 | -3.35 ± 18.38 | -4.57 ± 20.44 |
| Reflux Symptoms: Change at Cycle 18 | -2.94 ± 18.36 | -6.51 ± 20.33 |
| Reflux Symptoms: Change at Cycle 19 | -2.43 ± 16.38 | -6.15 ± 18.43 |
| Reflux Symptoms: Change at Cycle 20 | -1.85 ± 18.32 | -5.38 ± 18.63 |
| Reflux Symptoms: Change at Cycle 21 | -1.83 ± 18.44 | -4.19 ± 17.73 |
| Reflux Symptoms: Change at Cycle 22 | -3.81 ± 19.30 | -7.00 ± 19.65 |
| Reflux Symptoms: Change at Cycle 23 | -5.11 ± 17.03 | -6.98 ± 19.70 |
| Reflux Symptoms: Change at Cycle 24 | -4.07 ± 19.30 | -7.98 ± 18.19 |
| Reflux Symptoms: Change at Cycle 25 | -5.56 ± 18.86 | -5.71 ± 16.69 |
| Reflux Symptoms: Change at Cycle 26 | -4.99 ± 20.67 | -4.30 ± 21.98 |
| Reflux Symptoms: Change at Cycle 27 | -7.75 ± 20.51 | -6.75 ± 16.10 |
| Reflux Symptoms: Change at Cycle 28 | -7.12 ± 18.64 | -4.44 ± 11.56 |
| Reflux Symptoms: Change at PT Visit 1 | 0.88 ± 20.01 | -0.45 ± 22.92 |
| Reflux Symptoms: Change at PT Visit 2 | 0.56 ± 18.67 | -1.47 ± 22.28 |
| Taste: Cycle 1 (Baseline) | 13.79 ± 23.99 | 16.22 ± 25.49 |
| Taste: Change at Cycle 2 | 12.09 ± 28.78 | 6.61 ± 26.94 |
| Taste: Change at Cycle 3 | 16.72 ± 32.11 | 9.99 ± 30.16 |
| Taste: Change at Cycle 4 | 18.43 ± 34.70 | 11.07 ± 31.93 |
| Taste: Change at Cycle 5 | 17.61 ± 32.93 | 11.85 ± 30.25 |
| Taste: Change at Cycle 6 | 17.97 ± 31.20 | 11.82 ± 32.21 |
| Taste: Change at Cycle 7 | 16.25 ± 33.51 | 9.19 ± 31.09 |
| Taste: Change at Cycle 8 | 11.64 ± 29.81 | 3.29 ± 28.13 |
| Taste: Change at Cycle 9 | 9.22 ± 28.25 | 1.73 ± 26.30 |
| Taste: Change at Cycle 10 | 7.93 ± 26.41 | 1.63 ± 28.79 |
| Taste: Change at Cycle 11 | 4.96 ± 26.72 | 2.61 ± 26.91 |
| Taste: Change at Cycle 12 | 5.27 ± 24.82 | 0.24 ± 24.66 |
| Taste: Change at Cycle 13 | 4.08 ± 25.53 | -0.91 ± 25.33 |
| Taste: Change at Cycle 14 | 0.49 ± 25.66 | -5.28 ± 24.37 |
| Taste: Change at Cycle 15 | 3.08 ± 24.36 | -1.04 ± 26.25 |
| Taste: Change at Cycle 16 | 5.51 ± 27.90 | -3.57 ± 20.71 |
| Taste: Change at Cycle 17 | 4.80 ± 24.96 | -3.65 ± 23.28 |
| Taste: Change at Cycle 18 | 3.59 ± 23.87 | -4.29 ± 23.34 |
| Taste: Change at Cycle 19 | 3.13 ± 25.17 | -4.62 ± 15.45 |
| Taste: Change at Cycle 20 | 5.56 ± 27.78 | -3.76 ± 18.21 |
| Taste: Change at Cycle 21 | 6.33 ± 27.26 | -5.03 ± 17.78 |
| Taste: Change at Cycle 22 | 9.45 ± 30.04 | -4.35 ± 16.64 |
| Taste: Change at Cycle 23 | 8.99 ± 30.06 | 0.00 ± 23.00 |
| Taste: Change at Cycle 24 | 7.78 ± 28.37 | -5.13 ± 19.55 |
| Taste: Change at Cycle 25 | 3.21 ± 28.97 | -4.76 ± 18.33 |
| Taste: Change at Cycle 26 | 4.08 ± 34.45 | -3.23 ± 21.70 |
| Taste: Change at Cycle 27 | 4.65 ± 29.62 | -3.57 ± 20.96 |
| Taste: Change at Cycle 28 | 3.42 ± 21.35 | -6.67 ± 25.46 |
| Taste: Change at PT Visit 1 | 12.76 ± 34.59 | 9.06 ± 33.56 |
| Taste: Change at PT Visit 2 | 8.42 ± 31.35 | 6.67 ± 28.64 |
| micrograms per milliliter (μg/mL) | Pertuzumab + Trastuzumab + Chemotherapy |
|---|---|
| Cycle 1 | 258 ± 90.3 |
| Cycle 2 | 288 ± 83.7 |
| Cycle 4 | 341 ± 111 |
| Cycle 8 | 371 ± 127 |
| μg/mL | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Cycle 1 | 142 ± 86.8 | 139 ± 58.6 |
| Cycle 2 | 120 ± 46.6 | 120 ± 44.3 |
| Cycle 4 | 127 ± 50.9 | 129 ± 58.1 |
| Cycle 8 | 130 ± 50.8 | 147 ± 90.2 |
| μg/mL | Pertuzumab + Trastuzumab + Chemotherapy |
|---|---|
| Cycle 1 | NA ± NA |
| Cycle 2 | 42.4 ± 24.8 |
| Cycle 3 | 74.0 ± 40.9 |
| Cycle 4 | 90.4 ± 42.4 |
| Cycle 6 | 114 ± 51.8 |
| Cycle 8 | 142 ± 67.9 |
| μg/mL | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Cycle 1 | NA ± NA | NA ± NA |
| Cycle 2 | 15.4 ± 11.3 | 17.2 ± 15.4 |
| Cycle 3 | 19.9 ± 13.4 | 20.7 ± 15.2 |
| Cycle 4 | 22.9 ± 12.7 | 24.1 ± 19.0 |
| Cycle 6 | 26.3 ± 14.8 | 29.8 ± 21.9 |
| Cycle 8 | 32.7 ± 15.0 | 37.4 ± 20.3 |
Collected over From Baseline until end of post-treatment follow-up (up to 70 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy | 299/385 (77.7%) | 178/385 (46.2%) | 373/385 (96.9%) |
| Placebo + Trastuzumab + Chemotherapy | 318/388 (82%) | 156/388 (40.2%) | 376/388 (96.9%) |
| Event | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 17/385 | 20/388 |
| Decreased appetiteMetabolism and nutrition disorders | 17/385 | 9/388 |
| AnaemiaBlood and lymphatic system disorders | 8/385 | 16/388 |
| PneumoniaInfections and infestations | 14/385 | 14/388 |
| VomitingGastrointestinal disorders | 7/385 | 13/388 |
| DehydrationMetabolism and nutrition disorders | 9/385 | 9/388 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/385 | 9/388 |
| DeathGeneral disorders | 8/385 | 9/388 |
| SepsisInfections and infestations | 8/385 | 2/388 |
| NauseaGastrointestinal disorders | 7/385 | 7/388 |
| Event | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 230/385 | 125/388 |
| NauseaGastrointestinal disorders | 224/385 | 218/388 |
| NeutropeniaBlood and lymphatic system disorders | 200/385 | 202/388 |
| Decreased appetiteMetabolism and nutrition disorders | 172/385 | 158/388 |
| AnaemiaBlood and lymphatic system disorders | 159/385 | 142/388 |
| VomitingGastrointestinal disorders | 147/385 | 122/388 |
| FatigueGeneral disorders | 144/385 | 123/388 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 86/385 | 100/388 |
| ConstipationGastrointestinal disorders | 56/385 | 84/388 |
| StomatitisGastrointestinal disorders | 81/385 | 69/388 |
The Intent-to-Treat (ITT) population included all randomized participants regardless of whether treatment was actually received, with participants grouped according to the treatment assigned at randomization.
| Age, Continuous(Years) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Mean | 60.9 ± 11.3 | 60.1 ± 10.7 | 60.5 ± 11.0 |
| Sex: Female, Male(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Female | 94 | 69 | 163 |
| Male | 294 | 323 | 617 |
| Geographic Region(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Asia (excluding Japan) | 143 | 146 | 289 |
| Japan | 40 | 40 | 80 |
| North America/Western Europe/Australia | 133 | 133 | 266 |
| South America/Eastern Europe | 72 | 73 | 145 |
| Prior Gastrectomy(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Prior Gastrectomy | 105 | 102 | 207 |
| No Prior Gastrectomy | 283 | 290 | 573 |
| Human Epidermal Growth Factor Receptor 2 (HER2) Status(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| IHC 2+/ISH+ | 129 | 130 | 259 |
| IHC 3+ | 259 | 262 | 521 |
| Measurability of Disease, per RECIST v1.1(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Measurable Disease | 351 | 352 | 703 |
| Non-Measurable Evaluable Disease Only | 37 | 40 | 77 |
Showing the first 100 of 172 sites across 32 countries. Choose a country and city above to see the rest.
Ran from Jun 2013 to primary completion in Dec 2016, 41 months.
Results were first posted in Feb 2018, 1 year 2 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 41 months is close to that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab